Oral calcitriol: a new therapeutic agent in cutaneous lichen sclerosis

Journal of Drugs in Dermatology, Jan, 2003 by S Ronger, AM Viallard, Meunier-Mure F, B Chouvet, B Balme, L Thomas

(34.) Griffiths MR, Priestley GC. A comparison of morphea and lichen sclerosis et atrophicus in vitro: the effects of para amino benzoate on skin fibroblasts. Acta Derm Venereol 1992; 72:15-18.

(35.) Scully JP. Lichen sclerosis et atrophicus. Arch Dermatol 1958; 77:763.

(36.) Connelly MG, Winkelmann RK. Coexistence of lichen sclerosis. morphea and lichen planus. J Am Acad Dermatol 1985; 12:844-51

(37.) Buechner SA, Winkelmann RK, Lautenschlager S et al. Localized scleroderma associated with Borrelia Burgdorferi infection. J Am Acad Dermatol 1993; 29:190-6.

(38.) Bousema MT, Romppanen U, Geiger JM et al. Acitretin in the treatment of severe lichen sclerosis et atrophicus of the vulva: a double bind, placebo-controlled study. J Am Acad Dermatol 1994; 30:225-31.

(39.) Coskey RJ. Dermatologic therapy: December 1983 through November 1984. J Am Acad Dermatol 1985; 12:1045-71.

(40.) Sapadin AN, Fleischmajer R. Treatment of Scleroderma. Arch Dermatol 2002; 138: 99-105.

(41.) Humbert P, Aubin F, Dupont JL et al. Oral calcitriol as a new therapeutic agent in localized and systemic scleroderma. Arch Dermatol 1995; 131(7): 850-51.

(42.) Hulshof MM, Pavel S, Breedveld FC et al. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994; 130(10): 1290-93.

(43.) Humbert P, Delaporte E, Dupont JL et al. Treatment of localized scleroderma with oral 1-25 dihydroxyvitamin D3. Eur J Dermatol 1994; 4(1): 21-23.

(44.) Humbert P, Dupont JL, Agache P et al. Treatment of scleroderma with oral 1-25 dihydroxyvitamin D3: Evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 1993; 73(6): 449-451.

(45.) Delaporte E, Humbert P, Dupont JL et al. Sclerodermie en plaques: efficacite remarquable du 1-25 dihydroxycholecalciferol. Rev Med Interne 1993; 14(6):498.

(46.) Matsuoka LY, Dannenberg MJ, Worstman J et al. Cutaneous vitamin D3 formation in progressive systemic sclerosis. J Rheumatol 1991; 18(8):1196-98.

(47.) Dupont JL, Humbert P, Rochefort A et al. Treatment of systemic sclerosis and localized scleroderma with 1-25 dihydroxycholecalciferol Rev Med Interne 1991; 12:S26.

(48.) Humbert P, Dupont J, Rochefort A et al. Localized scleroderma, response to 1-25 dihydroxyvitamin D3. Clin Exp Dermatol 1990; 15(5):396-98.

(49.) Ballmer-Weber BK, Berchtold B. Calcitriol: an effective therapy for the treatment of morphea? Dermatology 1996; 193(2):162.

(50.) Caca-Bilijanovska NG, Vlckova-Laskosta MT, Dervendi DV, Pesic NP, Kaskoski DS. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999; 455:299-304.

(51.) Hulshof MM, Bouwes bavinck JN, Bergman W, Masclee AA et al. Double bind, placebo controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000; 43: 1017-23.

(52.) Elst EE, Van Suijlekom Smit LWA, Oranje AP. Treatment of Linear Sceroderma with oral 1,25. Dihydroxyvitamin D3 (Calcitriol) in seven children. Pediatric Dermatology 1999; 16:53-58.